Sepsis mediators

Sepsis mediators are a broad and heterogeneous group of endogenous and exogenous molecules that drive the dysregulated host response to infection, leading to life-threatening organ dysfunction [3, 5, 12]. This category encompasses pro-inflammatory and anti-inflammatory cytokines (such as tumor necrosis factor-alpha, interleukin-1, and interleukin-6), damage-associated molecular patterns (DAMPs) like high mobility group box 1 (HMGB1), and components of the complement and coagulation cascades [4, 7, 15]. These molecules act as signaling entities that amplify the systemic inflammatory response, activate endothelial cells, and disrupt microvascular perfusion [11, 12]. Therapeutic strategies have historically focused on neutralizing individual mediators or blocking their receptors to prevent the 'cytokine storm' and subsequent tissue damage [1, 9]. Despite their central role in pathology, clinical trials targeting single mediators have often failed due to the complexity and redundancy of the sepsis signaling network [14, 16]. Consequently, modern drug development is shifting toward more personalized approaches that consider the timing of mediator release and individual patient phenotypes [3, 13].

Other names

Inflammatory mediatorsSepsis-related cytokinesDamage-associated molecular patterns (DAMPs)Pathogen-associated molecular patterns (PAMPs)Circulating inflammatory factorsSeptic mediators

Pharmacological interventions target these mediators through various mechanisms, including the neutralization of circulating pro-inflammatory cytokines using monoclonal antibodies, competitive antagonism of cytokine or pattern recognition receptors (e.g., TLR4 antagonists), and the modulation of the complement or coagulation systems to restore homeostatic balance [3, 8, 9].